5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples